Nearly one-third (32.6 percent) of patients given low-dose voclosporin along with standard-of-care treatment achieved complete remission of their lupus nephritis at week 24 versus 27.3 percent of those given high-dose voclosporin and 19.3 percent of those given placebo, according to a new phase IIb study. “These preliminary results show great promise and could potentially change the current treatment paradigm for lupus nephritis,” chief investigator Mary Anne Dooley, MD, a rheumatologist in Chapel Hill, N.C., told MedPage Today.

Click here for more.